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Abstract The majority of cases of early-onset familial Alzhei- 
mer disease are caused by mutations in the recently identified 
presenilin 1 (PS1) gene, located on chromosome 14. PS1, a 467 
amino acid protein, is predicted to be an integral membrane 
protein containing seven putative transmembrane domains and a 
large hydrophilic loop between the sixth and seventh membrane- 
spanning domain. We produced 7 monoclonal antibodies that 
react with 3 non-overlapping epitopes on the N-terminal 
hydrophilic tail of PS1. The monoclonal antibodies can detect 
the full-size PS1 at Mr 47 000 and a more abundant Mr 28 000 
product in membrane xtracts from human brain and human cell 
lines. PC12 cells transiently transfected with PS1 constructs 
containing two different Alzheimer mutations fail to generate the 
28 kDa degradation product in contrast o PC12 cells transfected 
with wild-type PS1. Our results indicate that missense mutations 
in this form of familial Alzheimer disease may act via a 
mechanism of impaired proteolytic processing of PS1. 
Key words: Alzheimer disease; Chromosome 14; Presenilin; 
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1. Introduction 
The deposition of 13/A4-amyloid in the brain parenchyma 
and the presence of neurofibrillary degeneration i brain re- 
gions important for cognitive functions are typical for familial 
as well as sporadic forms of Alzheimer disease [1]. The bio- 
chemical processes leading to these lesions are, however, not 
well understood. 
To date, four different genes have been implicated to play a 
role in the disease process. The first gene identified in early- 
onset familial Alzheimer was the ~/A4-amyloid protein pre- 
cursor (APP) [2] and mutations in the APP gene account for 
less than 5% of the early-onset familial cases of AD. The APP 
gene is located on chromosome 21 and the observation that 
virtually all individuals with Down's syndrome acquire AD 
neuropathology in later life provides compelling evidence for 
a central role of this protein in the disease process of all 
Alzheimer patients. Another genetic factor identified is the 
inheritance of specific apolipoprotein E (apoE) alleles which 
determine the age of onset in both sporadic and late-onset 
familial Alzheimer disease [3]. The mechanism through which 
the apoE4 allele lowers the age of onset is still unknown. 
Mutations in two other genes, recently identified, account 
for the majority of the cases of early-onset familial Alzheimer 
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disease (for review see [4]). These two novel genes, named 
presenilin 1 (PS1) and presenilin 2 (PS2), are located on chro- 
mosome 14 and chromosome 1, respectively, and are highly 
homologous (67%). Sequence analysis predicts integral mem- 
brane proteins, that contain seven putative transmembrane 
domains, a short hydrophilic amino- and carboxyl-terminal 
tail, and a large hydrophilic loop between the sixth and sev- 
enth membrane-spanning domain. All of the reported muta- 
tions that result in early-onset Alzheimer's disease are mis- 
sense mutations, 24 in PSI [5 11] and two in PS2 [12,13], or 
mutations that affect the splicing without affecting the coding 
of the protein [14] and this has led to the hypothesis that they 
may result in a gain of (mis)function. This view is also con- 
sistent with a recent report describing that an intron poly- 
morphism in the PSI gene is related to approx. 20% of the 
cases of late-onset Alzheimer disease [15]. 
The high similarity in the pathology observed in familial 
and sporadic forms of Alzheimer's disease indicates converg- 
ing pathological mechanisms and clarification of the (mal)- 
function of the presenilins will most likely provide important 
clues for the disease process, not only in familial, but also in 
sporadic Alzheimer's disease. In this study we produced a 
series of mono- and polyclonal antibodies and started to in- 
vestigate the metabolism of normal and mutated PSI. We 
demonstrate hat in vivo PSI is expressed as a 47 kDa protein. 
Monoclonal antibodies, directed against amino-terminal epi- 
topes of PS1, also detect an abundant 28 kDa degradation 
product in extracts from human brain and human cell lines. 
We transfected PC12 cells with wild-type human PSI and two 
constructs containing Alzheimer mutations and observed 
striking differences in the proteolytic processing of PSI. Cells 
transfected with mutated PS1 showed a highly reduced capa- 
city to generate the 28 kDa product. 
Taken together, our results indicate that in vivo selective 
proteolysis of PS1 generates an abundant 28 kDa degradation 
product and that this process is affected by the mutations that 
cause Alzheimer's disease. 
2. Materials and methods 
2.1. Antibody production 
All synthetic peptides were coupled to Imject keyhole limpet hemo- 
cyanin (Pierce) before immunization. Hybridomas MKAD3.1- 
MKAD3.7 were isolated after immunization of Balb/c mice with a 
synthetic peptide containing the amino acid residues 21-59 (N-pep- 
tide) of human presenilin 1[5]. Fusion and culture procedures were as 
described elsewhere [16]. Polyclonal rabbit antisera were obtained 
after immunization with synthetic peptides panning residues 299- 
313 (serum PSI-M) and 453467 (C-peptide, serum PSI-C). 
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2.2. Epitope mapping 
Overlapping octapeptides for epitope mapping were synthesized on 
polypropylene pins arranged in a microtiter plate format using the 
Multipin Peptide Synthesis System (Chiron Mimotopes). Antibody 
reactivity with octapeptides was determined by ELISA using tetra- 
methylbenzidine (Boehringer) as substrate and absorbances were 
read at 450 nm. Readings more than 3 times higher than background 
were considered as positive signals. 
2.3. Constructs 
Full-length PS1 DNA was amplified by RT-PCR from human 
brain, inserted in pGEM-T (Promega) and, after subcloning, se- 
quenced using the ThermoSequenase fluorescent labeled primer cycle 
sequencing kit (Amersham). The clone lacks the 4 amino acids 
(VRSQ) which are encoded by the last 12 base pairs of exon 3. Alz- 
heimer mutations Met146Val and Ala246Glu were introduced by PCR- 
based site-directed mutagenesis and confirmed by sequencing using 
the same method. 
2.4. GST-PS1 fusion protein purification 
Full-size PSI cDNA was subcloned into pGEX-4T-1 (Pharmacia). 
GST-PS1 fusion protein expression was induced with 1 mM isoprop- 
yl-13-o-thiogalactopyranoside (IPTG) for 2 h at 37°C. After harvest- 
ing, cells were resuspended in 50 mM Tris, pH 7.4, 150 mM NaC1 
(Tris-Sal) containing 1% Triton X-100, 5 mM DTT, 5 mM EDTA, 1 
mM Pefabloc, 5 ~tg/ml pepstatin, 10 lag/ml leupeptin and lysed by 
sonication twice for 1 min with a Souifier Cell Disruptor (Heat Sys- 
tems-Ultrasonics) using a microprobe. Lysates were cleared by centrif- 
ugation, filtered and loaded overnight at 4°C on a glutathione-agarose 
column (Sigma). GST-PS1 fusion proteins were eluted by adding 15 
mM reduced glutathione (Sigma) to the buffer. 
2.5. PSI immunoaffinity purification 
Monoclonal antibody MKAD3.3 was purified from culture super- 
natant on protein G (Pharmacia) and coupled to CNBr-activated 
Sepharose 4B (Pharmacia). Membrane xtracts were prepared as de- 
scribed below and loaded overnight at 4°C. After washing with 10 
column volumes Tris-Sal, 1% Triton X-100, proteins were eluted in 
0.1 M glycine, 0.1% Triton X-100, pH. 2.7 and the pH of the fractions 
was neutralized immediately with 1 M Tris, pH 9.0 (50 ktl/ml). 
2.6. Preparation of membrane fractions 
Membrane fractions from human cell lines and adult human brain 
(neocortex) were prepared as follows. Homogenates, prepared with 50 
mM Tris, pH 7.4, 150 mM NaC1 (Tris-Sal) were centrifuged at 
12 000 ×g, pellets were extracted with Tris-Sal containing 1% Triton 
X-100, recentrifuged at 12 000 × g, and the supernatant collected. Pro- 
tease inhibitor cocktail was added to all buffers (1 mM Pefabloc, 5 ktg/ 
ml pepstatin, 2.5 mM EDTA, 10 ~g/ml eupeptin). 
2.7. Transfections 
For transfection, wild-type and mutant PS1 cDNA was subcloned 
in pEF321 [17]. PC12 cells were transfected using LipofectAMINE 
(GibcoBRL) and total cell extracts were prepared 72 h later by lysis 
in modified RIPA buffer (50 mM Tris-HC1, pH 7.4, 1% NP-40, 0.25% 
sodium deoxycholate, protease inhibitors as above). The lysates were 
centrifuged in a microcentrifuge at 15 000 rpm at 4°C, the supernatant 
was collected and equal amounts of protein were separated in SDS- 
PAGE and immunoblotted asdescribed in Section 2.9. 
2.8. Mammalian cell cultures 
Human SH-SY neuroblastoma cells and 293 kidney cells were cul- 
tured in DMEM containing 4.5 mg/ml D-glucose (GibcoBRL) supple- 
mented with 10% FBS (fetal bovine serum) at 37°C in a 5% CO2 
atmosphere. Rat PC12 cells were cultured in DMEM containing 4.5 
mg/ml D-glucose (GibcoBRL) supplemented with 5% FBS and 5% HS 
(horse serum) at 37°C in a 10% CO2 incubator. Gentamicin sulfate at 
84 mg/1 was added in all media to prevent bacterial growth. 
2.9. Western blot analysis 
Proteins were separated in 10% SDS-PAGE and transferred to ni- 
trocellulose membranes (Schleicher and Schuell). Samples were not 
heated before loading except when indicated. When applied, heating 
was for I0 min at 100°C. Membranes were blocked by 10% milk in 
PBS, 0.1% Tween 20. Primary antibodies were diluted in 5% milk in 
PBS, 0.05% Tween 20 (hybridoma supernatant 1:5 and rabbit serum 
1:1000) and incubated overnight at 4°C or 2 h at room temperature. 
Monoclonal antibodies were detected with rabbit anti-mouse Ig per- 
oxidase conjugate (Zymed) (Fig. 2, Fig. 3 (pre, post and eluate frac- 
tions from brain), and Fig. 4) or biotinylated goat anti-mouse IgG 
followed by streptavidin-peroxidase conjugate (Amersham) (Fig. 3, 
lanes 1-10 from brain and lanes 1-8 and pre, post and eluate fractions 
from SH-SY). Rabbit polyclonals were developed with rabbit anti- 
mouse Ig peroxidase conjugate (Zymed). Peroxidase was detected by 
ECL (Amersham), except in Fig. 2a, lanes 2 and 4-6 where diamino- 
benzidine (Sigma) was used as a substrate. 
In the preabsorption experiments 200 ~1 of the diluted antibody was 
preincubated with 100 ~tl of the synthetic peptides at 250/.tg/ml for 4 h 
at room temperature. 
3. Results 
3.1. Production of mono- and polyclonal antibodies against 
presenilin 1 
Seven IgG monoclonal antibodies, termed MKAD3.1 -  
MKAD3.7,  were isolated after immunization with a synthetic 
peptide, containing residues 21 59 of the hydrophilic amino- 
terminus of human PS1. Epitope mapping, using the multipin 
method, showed that the antibodies can be divided in three 
groups according to their reactivity with 3 different non-over- 
lapping epitopes (Fig. lb). One monoclonal antibody, 
MKAD3.7,  reacts with amino acid residues 27-32. This epi- 
tope contains part of the VRSQ sequence known to undergo 
alternative splicing in vivo [6]. The two other epitopes contain 
amino acid residues 36-39, recognized by both MKAD3.2 and 
MKAD3.6 and amino acid residues 45-48 recognized by 
MKAD3.1 and MKAD3.3-MKAD3.5.  
We confirmed the specificity of the antibodies by their re- 
activity with bacterially expressed glutathione-S-transferase 
fusion proteins of full-size presenilin 1 (GST-PS1) (Fig. 2a). 
MKAD3.7 was the only monoclonal antibody that showed no 
reaction with the purified GST-PS1 fusion protein. This was 
not unexpected since our recombinant construct lacks the al- 
ternatively spliced VRSQ sequence which is part of the 
MKAD3.7 epitope. Preincubation of the monoclonal antibod- 
ies with the synthetic peptide used for immunization, but not 
with control peptide, eliminates the binding to the GST-PS1 
fusion protein (Fig. 2a and data not shown). The GST-PS1 
fusion protein was highly sensitive to aggregation when 
heated in SDS-PAGE sample buffer, a known characteristic 
of other hydrophobic integral membrane proteins [18] and 
also observed by others [19] for in vitro translated PS1. 
We also raised two different polyclonal rabbit antisera, 
named PS1-M and PS1-C, directed against synthetic peptides 
of regions in the large hydrophilic loop (PSI-M) and the C 
terminus (PS1-C) of PS1 (Fig. la). The reactivity of both 
antisera with full-size presenilin 1 was also confirmed using 
bacterially expressed glutathione-S-transferase fusion proteins 
(Fig. 2a) and this binding can be inhibited specifically by 
preincubation with the synthetic peptide used for immuniza- 
tion (data not shown). 
3.2. Presenilin 1 protein expression in human cell lines and 
human brain 
The monoclonal antibodies were subsequently used to char- 
acterize PS1 protein in membrane xtracts from human SH- 
SY neuroblastoma cells, human 293 kidney cells and human 
brain (Fig. 2b). In all three extracts the antibodies MKAD3.3 
and MKAD3.7 were able to detect a band at Mr 47000, 
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Fig. 1, Production of monoclonal and polyclonal antibodies against presenilin 1 (PS1). (a) Model of the putative seven transmembrane struc- 
ture of PS1. Thick lines indicate the location of the peptide sequences used for immunization in the production of monoclonal antibodies 
(N-terminal, amino acids 21-59) and polyclonal antibodies (hydrophilic loop, amino acids 29%313 (PS1-M); C-terminal, amino acids 453467 
(PSI-C)). (b) Epitope mapping of monoclonal antibodies by use of the multipin method. The antibodies are divided into 3 groups according to 
3 non-overlapping epitopes. The positive reaction of a representative monoclonal antibody of each group with individual octapeptides i  indi- 
cated by + and the corresponding epitope is indicated as a boxed sequence. The shaded area represents a site which is subject o alternative 
splicing in vivo. 
which we believe corresponds to full-size PS1. The faster mi- 
gration than the Mr 52000 calculated from the DNA se- 
quence is not surprising for a highly hydrophobic protein 
[20] and has also been reported for PS1 by others [19]. The 
appearance as a sharp single band may indicate the lack of 
extensive posttranslational modifications. A second and 
stronger signal, detected with all monoclonal antibodies, was 
observed at approx. 28 kDa. Both signals are not detected 
when the sample is heated before loading, a property shared 
with the GST-PS1 fusion protein. In the extract from post- 
mortem human brain we detected, in addition to the 28 kDa 
band, a small amount of products larger than 28 kDa but 
smaller than 47 kDa. They may represent non-specific post- 
mortem degradation of the full-size 47 kDa protein, most 
likely to occur primarily within the exposed hydrophilic 
loop. In contrast o post-mortem brain, the human cell-lines 
contain almost exclusively the 47 and 28 kDa products. For 
this reason we believe that, in vivo, PS1 undergoes elective 
cleavage at or near the beginning of the hydrophilic loop. 
3.3. Immunoaffinity purification of PS1 from human brain and 
SH-SY cells 
To further characterize these products, we prepared an af- 
finity column using the monoclonal antibody MKAD3.3 and 
purified PS1 from SH-SY cells and from human brain (Fig. 3). 
We obtained highly enriched fractions containing both the 47 
and the 28 kDa proteins. The purified proteins were evaluated 
by immunoblot with all seven amino-terminal specific mono- 
clonal antibodies and with the two polyclonal rabbit antisera 
raised against regions in the large hydrophilic loop and the C 
terminus of PS1. As expected, the 47 kDa protein is recog- 
nized not only by all seven monoclonal antibodies but also by 
both polyclonal antisera, confirming its identity as full-size 
PS1. The 28 kDa band, however, is only seen after staining 
with the amino-terminal specific monoclonal antibodies and is 
not reactive with the antisera raised against he hydrophilic 
loop and the carboxyl-terminus of PS1. The apparent molec- 
ular weight and the pattern of mono- and polyclonal anti- 
body reactivity are in agreement with the previously men- 
tioned proposition that, in vivo, PS1 is processed by specific 
cleavage at or near the beginning of the hydrophilic loop. 
3.4. Wild-type and mutant presenilin 1 in transfected pcl2 cells 
Next, we transfected rat PC12 cells with wild-type human 
PS1 and two constructs, containing the Meta46Val and 
Ala246Glu Alzheimer mutations (Fig. 4). The endogenous rat 
PS1 is not recognized by monoclonal antibody MKAD3.3 
(Fig. 4, lane 3) which enabled us to confirm that human 
PS1 is expressed as a 47 kDa protein. This experiment also 
clearly shows that a 28 kDa proteolytic product is generated 
in living cells after transfection with full-size human PS1 (Fig. 
4, lanes 2,5) and argues against he possibility that the 28 kDa 
product is generated by alternative splicing or alternative 
translation initiation. In contrast, PC12 cells transfected 
with constructs containing the Alzheimer mutations produce 
little or no 28 kDa protein (Fig. 4, lanes 1,4), indicating that 
these mutations alter the proteolytic processing of PS1 in the 
transfected cells. 
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Fig. 2. Confirmation of antibody specificity and detection of PS1 in human brain and cell lines. (a) Reactivity of different antisera with bacte- 
rially expressed glutathione-S-transferase fu ion proteins of full-size presenilin 1 (GST-PS1). No signal was detected in total cell-lysates from 
non-transformed E. coli cells (lane 2). The amount GST-PS1 loaded in lanes 3 17 is below the detection limit for ponceau red protein staining 
(lane 3). GST-PS1 is immunostained at Mr 75000 (75K), degradation products and aggregation are also observed. In lanes 5 and 6 the anti- 
body was preincubated with control peptide (C-peptide) or the peptide used for immunization (N-peptide). The 75K band aggregates when the 
sample is heated before loading (lane 8). All monoclonal and polyclonal antisera, except MKAD3.7 (lane 14) and preimmune rabbit serum 
(prePS1-C, lane 15), react at 75K. Note the non-PSi reactivity of the preimmune serum at approx. Mr 65000 (#). (b) Detection of heat-sensi- 
tive PS1 a 47 and 28 kDa in membrane xtracts from human cell lines and human brain with 3 different monoclonal antibodies. Note the 
cross-reaction with non-heat-sensitive proteins for MKAD3.3 and MKAD3.7 (.). These bands are not present in affinity-purified products (Fig. 
3) and probably represent non-specific binding arising upon denaturation. Bands indicated by (~)  are reactive with the secondary antibody. 
Prestained molecular weight markers (GibcoBRL) were used. 
4. D iscuss ion  
Presenilins are becoming increasingly important  for our un- 
derstanding of the biochemical processes that lead to Alzhei- 
mer's disease. Antibodies to PSI are reactive with plaques in 
all amyloid-13-related amyloidoses [21], whether or not they 
were linked to chromosome 14 and a recent report [15] indi- 
cates a genetic association between an intronic polymorphism 
in the PS1 gene and late-onset Alzheimer's disease. The con- 
verging mechanisms that lead different genotypes to similar 
Alzheimer's disease pathology may therefore all include pre- 
senilins in their pathway. 
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Fig. 3. MKAD3.3 immunoaffmity purification of PS1 from human brain and SH-SY cells. Purification profiles show extracts before loading 
(pre), the flow-through fraction (post), and purified fractions (eluate). The eluate fractions contain highly enriched concentrations of 47 and 28 
kDa proteins. The top fraction was tested with different monoclonal and polyclonal antibodies. Bands caused by the secondary antisera re in- 
dicated by (#). (a) Human brain. Polyclonal antisera PS1-M and PS1-C do not recognize the 28K product (lane 12,13) indicating that the pro- 
teolytic cleavage is located before or at the beginning of the hydrophilic loop. Lane 10 is without primary antibody and lane 11 is with preim- 
mune rabbit serum (prePSl-C). Biotinylated molecular weight markers (Amersham) were used (lane 1). Note that all purified fractions (eluate 
fractions, lanes 1,3 9) contain reactive products at approx. 48 65 kDa, which are not detected with the polyclonal antibodies and probably rep- 
resent aggregated 28 kDa product. (b) SH-SY neuroblastoma cells. Lane 8 is without primary antibody. 
A recent study showed, by using in situ hybridization tech- 
niques, that presenilin expression in brain is almost exclusively 
restricted to neuronal populations [22]. In vitro translation 
and transfection experiments in that study have shown that 
recombinant FLAG-tagged proteins of PS1 and PS2 appear in 
SDS-PAGE at approximate Mr 50 000 but no differences were 
observed in the migration patterns for wild-type or mutant 
proteins. 
In our study we produced antibodies against different re- 
gions of presenilin 1 in order to investigate in more detail the 
in vivo metabolism of this protein. The use of highly specific 
and sensitive monoclonal antibodies allowed us to detect PS1 
in membrane xtract from human cell lines and human brain. 
The reactivity of the monoclonal antibodies with a Mr 47 000 
product is as expected for the full-size PS1 and probably cor- 
responds to the bands at approximate Mr 50 000 observed by 
others [19] after in vitro expression. These authors and others 
[19] also report higher molecular weight smears which are 
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Fig. 4. Western blot using the monoclonal antibody MKAD3.3 
showing transfection of PC12 cells with human wild-type PS1, hu- 
man mutant PS1 or LipofectAMINE only (control). Cells trans- 
fected with two different Alzheimer mutants produce 47 kDa full- 
size PSI but not the 28 kDa degradation product (lanes 1,4), The 
bands indicated by (*) are products which are not affected by the 
mutations. 
generated after extensive xposure to SDS, a characteristic for 
highly hydrophobic membrane proteins [18]. Our monoclonal 
antibodies detect similar smears, with loss of 47 kDa detec- 
tion, when the samples are heated before loading. In all ex- 
tracts tested, the 47 kDa signal was minor compared to a 
much more abundant signal at 28 kDa. This 28 kDa product 
was detected by 7 monoclonal antibodies against 3 non-over- 
lapping epitopes, hereby virtually excluding the possibility 
that it is the result of crossreactivity and not related to PS1. 
In some experiments his 28 kDa band appeared as a closely 
spaced doublet (unpublished results) of which the origin is 
uncertain but which may indicate the presence of the isoform 
missing the alternatively spliced VRSQ sequence ncoded by 
the last 12 base pairs of exon 3. Affinity-purified 28 kDa 
products showed no reactivity with 2 polyclonal antisera di- 
rected against he first part of the large hydrophilic loop and 
the carboxyl-terminus of PSI. It is unlikely that the 28 kDa 
product we observed is the truncated form, presenilin 1-374, 
that was recently described [22], since presenilin 1-374 is not 
expressed in brain. In addition, the absence of reactivity with 
our polyclonal antiserum PSI-M, directed against the loop 
region, also indicates that 28 kDa is different from presenilin 
1-374. The possibility that the 28 kDa product in the different 
human cell-lines and in human brain is generated by alterna- 
tive splicing or cross-reaction with another member of the 
presenilin gene family cannot be ruled out completely, but 
the observation that expression of human PS1 cDNA in 
PC12 cells, where there is no such possibility, leads to a simi- 
lar 28 kDa product strongly suggests otherwise. The fact that 
the N-terminal sequence of PSI is not well conserved may 
explain why the MKAD3.3 antibody shows no cross-reactiv- 
ity with endogenous rat PSI in PC12 cells and also argues 
against the possibility that in human cells the detection of 
the 28 kDa band is caused by cross-reaction with other mem- 
bers of the presenilin family. Thus, we can conclude that in 
vivo an amino-terminal polypeptide of 28 kDa, approx. 300 
amino acids, is generated by cleavage of PSI and that the 
proteolytic site is located at or near the beginning of the large 
hydrophilic loop. 
This region of the protein contains a hotspot for Alzheimer 
mutations [4] and it has been reported that deletion of exon 9 
(bp 857-942) can cause early-onset Alzheimer disease [14]. 
These genetic findings point to the possible importance for 
this part of the protein in the pathological processes leading 
to Alzheimer disease and encouraged us to study the effect of 
more remote mutations on proteolysis at this location. Our 
results in transfected PC12 cells indeed indicate that the Alz- 
heimer mutations at Met146Val and Ala246Glu inhibit the pro- 
teolysis that generates this 28 kDa product. In contrast, ex- 
pression of wild-type PS1 under the same experimental 
conditions does lead to a 28 kDa fragment. 
Clearly, more mutations need to be tested to confirm this 
relationship but from the above results it becomes tempting to 
speculate that the proposed gain of function of mutated PS1 
in Alzheimer's disease is a consequence of interference with 
the normal proteolytic turn-over, resulting in excessive activity 
of the protein. This can happen in a direct way by a change in 
the sequence of a major proteolytic site. One such site, as 
shown above, is located at or near the beginning of the large 
hydrophilic loop, a known hot spot for Alzheimer mutations. 
Proteolysis at this site can also be affected indirectly through 
the induction of conformational changes. This scenario would 
apply for the mutations tested here. The fact that the muta- 
tions tested, although located at more amino-terminal posi- 
tions, do affect the proteolysis of PS1 at a site presumed to be 
located in exon 8 or 9 only accentuates the possible impor- 
tance of this region. The accessibility for the possibly mem- 
brane associated protease that cleaves PS1 may be altered by 
small changes in the anchoring of PS1 in the membrane. The 
different mutations can be interfering with this process to a 
different extent resulting in a characteristic age of onset in the 
affected family. 
Mutations may also affect the proteolysis of PS1 by other 
mechanisms. The altered protein can be misrouted and simply 
never reach the location in the cell where it is normally 
cleaved. The abundant and selective appearance of the 28 
kDa product in vivo however is likely to reflect a physiologi- 
cal process in some way related to the function of PS 1, which 
could include the release of active C-terminal fragments. 
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These hypotheses remain to be tested but the differences 
observed in the processing of wild-type and mutated PSI in 
PC12 cells likely reflect similar metabolic events in the adult 
brain. Understanding of the possible relationship between this 
phenomenon and the processes that lead to [3-amyloid eposi- 
tion and neurofibrillary degeneration may inspire to novel 
therapeutic approaches for Alzheimer's disease. 
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